Market Overview:
The global fast-disintegrating tablets market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of chronic diseases, rising geriatric population, and growing demand for fast-disintegrating tablets due to their benefits over conventional tablets. Based on type, the global fast-disintegrating tablets market is segmented into anti-psychotics drug, anti-epileptics drug, and other types. The anti-psychotics drug segment is expected to account for the largest share of the global fast-disintegrating tablets market in 2018. This segment is projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030.
Product Definition:
A fast-disintegrating tablet is a type of tablet designed to dissolve quickly in the mouth, without the need for water. They are often used to provide relief from symptoms such as pain or nausea. Fast-disintegrating tablets can be especially helpful for people who have difficulty swallowing pills or who experience nausea when taking traditional tablets.
Anti-Psychotics Drug:
Anti-psychotics drug is a group of medicines used to treat mental disorders such as schizophrenia, mania, and bipolar disorder. Anti-psychotics drugs are also used for the treatment of severe depression and aggressive behavior associated with dementia. The global anti-psychotics drug market is expected to grow at an approximate CAGR of XX% over the forecast period owing to growing prevalence rates of mental disorders coupled with increasing awareness levels amongst patients & physicians regarding available treatments.
Anti-Epileptics Drug:
Anti-epileptics drug is used for the treatment of seizures. Anti-epileptic drugs are also known as antiseizure drugs or anti - epilepsy drugs. They are mainly used to prevent seizures and can be taken regularly to reduce the frequency of occurrence, if not remove them completely from your system.
The global fast disintegrating tablets market is expected to witness significant growth over the forecast period owing to increasing prevalence rate of epilepsy.
Application Insights:
CNS diseases segment dominated the global market in 2017. This can be attributed to the high prevalence of CNS disorders, such as Alzheimer¢â‚¬â„¢s disease, Parkinson¢â‚¬â„¢s disease, and epilepsy among other neurological conditions. Moreover, an increase in drug costs is expected to drive consumers towards low-cost generic drugs that have a shorter treatment duration and are more effective than branded products. This trend is projected to benefit fast-disintegrating tablets over the next eight years.
The gastrointestinal diseases segment is expected to grow at a lucrative rate during the forecast period owing to increasing incidences of functional gastrointestinal disorders coupled with rising awareness about NCDs including obesity & related health issues.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing cases of neurological, gastrointestinal, and other diseases coupled with rising adoption of fast-disintegrating tablets. Moreover, presence of key manufacturers such as Actavis and Shire also contributes toward growth in this region.
Asia Pacific is anticipated to be the fastest-growing regional market from 2018 to 2030 owing to growing geriatric population base and improving healthcare facilities for CNS disorders treatment in emerging economies such as China & India. Furthermore, increasing disposable income levels will also boost demand for these drugs over the forecast period. In addition, rapidly developing medical tourism industry will further propel growth during the forecast period (Hoffman et al., 2016).
Growth Factors:
- Increasing demand for fast-disintegrating tablets due to their benefits over conventional tablets
- Rising prevalence of chronic diseases, which is expected to increase the demand for fast-disintegrating tablets
- Technological advancements in the manufacturing of fast-disintegrating tablets that will make them more user friendly
- Growing number of research and development activities focused on the development of novel drug delivery systems, including fast-disintegrating tablets
- Rising geriatric population, who are more susceptible to chronic diseases, will drive the demand for fast-disintegrating tablets
Scope Of The Report
Report Attributes
Report Details
Report Title
Fast-disintegrating Tablets Market Research Report
By Type
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
By Application
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
By Companies
Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Teva
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
137
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global Fast-disintegrating Tablets Market Report Segments:
The global Fast-disintegrating Tablets market is segmented on the basis of:
Types
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Merck
- Mylan
- Pfizer
- Johnson and Johnson
- GSK
- Otsuka
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Teva
Highlights of The Fast-disintegrating Tablets Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-Psychotics Drug
- Anti-Epileptics Drug
- Other
- By Application:
- CNS Diseases
- Gastrointestinal Diseases
- CVS Diseases
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fast-disintegrating Tablets Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fast-disintegrating tablets are a type of medication that disintegrates quickly in the stomach, which is supposed to make them easier to swallow.
Some of the major players in the fast-disintegrating tablets market are Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Teva.
The fast-disintegrating tablets market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fast-disintegrating Tablets Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fast-disintegrating Tablets Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fast-disintegrating Tablets Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fast-disintegrating Tablets Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fast-disintegrating Tablets Market Size & Forecast, 2018-2028
4.5.1 Fast-disintegrating Tablets Market Size and Y-o-Y Growth
4.5.2 Fast-disintegrating Tablets Market Absolute $ Opportunity
Chapter 5 Global Fast-disintegrating Tablets Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Fast-disintegrating Tablets Market Size Forecast by Type
5.2.1 Anti-Psychotics Drug
5.2.2 Anti-Epileptics Drug
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Fast-disintegrating Tablets Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Fast-disintegrating Tablets Market Size Forecast by Applications
6.2.1 CNS Diseases
6.2.2 Gastrointestinal Diseases
6.2.3 CVS Diseases
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fast-disintegrating Tablets Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fast-disintegrating Tablets Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Fast-disintegrating Tablets Analysis and Forecast
9.1 Introduction
9.2 North America Fast-disintegrating Tablets Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Fast-disintegrating Tablets Market Size Forecast by Type
9.6.1 Anti-Psychotics Drug
9.6.2 Anti-Epileptics Drug
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Fast-disintegrating Tablets Market Size Forecast by Applications
9.10.1 CNS Diseases
9.10.2 Gastrointestinal Diseases
9.10.3 CVS Diseases
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Fast-disintegrating Tablets Analysis and Forecast
10.1 Introduction
10.2 Europe Fast-disintegrating Tablets Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Fast-disintegrating Tablets Market Size Forecast by Type
10.6.1 Anti-Psychotics Drug
10.6.2 Anti-Epileptics Drug
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Fast-disintegrating Tablets Market Size Forecast by Applications
10.10.1 CNS Diseases
10.10.2 Gastrointestinal Diseases
10.10.3 CVS Diseases
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Fast-disintegrating Tablets Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Fast-disintegrating Tablets Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Fast-disintegrating Tablets Market Size Forecast by Type
11.6.1 Anti-Psychotics Drug
11.6.2 Anti-Epileptics Drug
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Fast-disintegrating Tablets Market Size Forecast by Applications
11.10.1 CNS Diseases
11.10.2 Gastrointestinal Diseases
11.10.3 CVS Diseases
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Fast-disintegrating Tablets Analysis and Forecast
12.1 Introduction
12.2 Latin America Fast-disintegrating Tablets Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Fast-disintegrating Tablets Market Size Forecast by Type
12.6.1 Anti-Psychotics Drug
12.6.2 Anti-Epileptics Drug
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Fast-disintegrating Tablets Market Size Forecast by Applications
12.10.1 CNS Diseases
12.10.2 Gastrointestinal Diseases
12.10.3 CVS Diseases
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Fast-disintegrating Tablets Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Fast-disintegrating Tablets Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Fast-disintegrating Tablets Market Size Forecast by Type
13.6.1 Anti-Psychotics Drug
13.6.2 Anti-Epileptics Drug
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Fast-disintegrating Tablets Market Size Forecast by Applications
13.10.1 CNS Diseases
13.10.2 Gastrointestinal Diseases
13.10.3 CVS Diseases
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fast-disintegrating Tablets Market: Competitive Dashboard
14.2 Global Fast-disintegrating Tablets Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Merck
14.3.3 Mylan
14.3.4 Pfizer
14.3.5 Johnson and Johnson
14.3.6 GSK
14.3.7 Otsuka
14.3.8 Eli Lilly and Company
14.3.9 AstraZeneca
14.3.10 Bristol-Myers Squibb
14.3.11 Teva
